HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
April 08, 2021 03:30 ET | Hutchison China MediTech Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
March 29, 2021 02:00 ET | Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated two international Phase I...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
March 24, 2021 09:30 ET | Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it has reached an...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
March 24, 2021 03:00 ET | Hutchison China MediTech Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in...
HUTCHMED-spaced-1000x1000-WhiteBgd.jpg
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
March 04, 2021 07:00 ET | Hutchison China MediTech Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), an innovation-driven, commercial-stage...
HCM Hutchison China MediTech tall 129x150.png
Chi-Med to Announce 2020 Final Results
February 03, 2021 02:00 ET | Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the...
HCM Hutchison China MediTech tall 129x150.png
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
January 14, 2021 05:00 ET | Hutchison China MediTech Limited
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in...
HCM Hutchison China MediTech tall 129x150.png
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
January 10, 2021 20:00 ET | Hutchison China MediTech Limited
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals...
HCM Hutchison China MediTech tall 129x150.png
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
December 30, 2020 07:00 ET | Hutchison China MediTech Limited
– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial...
HCM Hutchison China MediTech tall 129x150.png
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
December 28, 2020 13:25 ET | Hutchison China MediTech Limited
– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS...